

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 03063-0381	SERIAL NO. 09/491,146	FILING DATE <del>Concurrently Herewith</del> 01/25/2000
APPLICANT Yury E. Khudyakov and Howard A. Fields		GROUP 1643/642

135 U.S. PTO  
09/491146  
01/25/00

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
bf	AA	5,625,034	4/29/97	Liao et al.			
bf	AB	5,443,965	8/22/95	Reyes et al.			
bf	AC	5,538,865	7/23/96	Reyes et al.			
bf	AD	5,436,126	7/25/95	Wang			
bf	AE	5,563,032	10/8/96	Fields et al.			
bf	AF	5,574,132	11/12/96	Lacroix			
bf	AG	5,436,318	7/25/95	Reyes et al.			
bf	AH	5,302,507	4/12/94	Chiba et al.			
bf	AI	5,106,726	4/21/92	Wang			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.	
bf	AJ	95/21858	17.08.95	International	USA		
bf	AK	97/05164	13.02.97	Australia	CSL Ltd.		
bf	AL	95/09239	06.04.95	International	President and Fellows of Harvard College		

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

bf	AM	"Detection of Antibodies to Hepatitis C Virus (HCV) Structural Proteins in Anti-HCV-Positive Sera by an Enzyme-Linked Immunosorbent Assay Using Synthetic Peptides as Antigens"; Chuzo Ishida et al. <u>Journal of Clinical Microbiology</u> , Vol. 31, No. 4, Apr. 1993, pp. 936-940
bf	AN	"E2 and NS5: New Antigens for Detection of Hepatitis C Virus Antibodies"; H.L. Zaaijer et al., <u>Journal of Medical Virology</u> , 44:395-397, April 25, 1994,
bf	AO	"Improved Diagnosis of Chronic Hepatitis C Virus Infection by Detection of Antibody to Multiple Epitopes: Confirmation by Antibody to Synthetic Oligopeptides", D. Brown et al., <u>Journal of Medical Virology</u> , 38:167-171, April 3, 1992
bf	AP	"Preformed Antigen-Antibody Complex to Detect Antibodies to Hepatitis C Virus", Dinesh Shah, <u>Clinical Chemistry</u> , Vol 41, No. 9, 1357- 58, 1995
bf	AQ	"Study on Reliability of Commercially Available Hepatitis C Virus Antibody Tests", H.H. Feucht et al., <u>Journal of Clinical Microbiology</u> , Vol. 33, No. 3, Mar. 1995, pp. 620-624

EXAMINER Freunda Pounback	DATE CONSIDERED 9-6-2001
------------------------------	-----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM FTC-1449, Adapted

# LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE
03063-0381		09/491,146	Concurrently Herewith 1/28/2000
APPLICANT		GROUP	
Yury E. Khudyakov and Howard A. Fields		1643 1642	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
bf	BA	"Synthetic gene for the hepatitis C virus nucleocapsid protein", Y. E. Khudyakov et al., <u>Nucleic Acids Research</u> , Vol. 21, No. 11, pp. 2747-2754, April 30, 1993	
bf	BB	"IgM and IgG Antibodies to Hepatitis E Virus (HEV) Detected by an Enzyme Immunoassay Based on an HEV-Specific Artificial Recombinant Mosaic Protein", M.O. Favorov, <u>Journal of Medical Virology</u> , 50:50-58, May 9, 1996	
bf	BC	"Artificial Mosaic Protein Containing Antigenic Epitopes of Hepatitis E Virus"; Yury E. Khudyakov et al., <u>Journal of Virology</u> , Vol. 68, No. 11, Nov. 1994, pp. 7067-7074	
bf	BD	"Solid-phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides", George J. Dawson et al., <u>Journal of Virological Methods</u> , 38 (1992) pp. 175-186	
bf	BE	"Influence of Viraemia and Genotype Upon Serological Reactivity in Screening Assays for Antibody to Hepatitis C Virus", S.K. Dhaliwal et al., <u>Journal of Medical Virology</u> , 48:184-190 (1996)	
bf	BF	"Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein", Barbara Hosein et al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 88, May 1991, pp. 3647-3651	
bf	BG	"Hepatitis E. virus (HEV): The novel agent responsible for enterically transmitted non-A, non-B hepatitis", Gregory R. Reyes et al., <u>Gastroenterologia Japonica</u> , Vol. 26, Suppl. 3, July 1991, pp. 142-147	
bf	BH	"To C or Not to C: These are the Questions", Harvey J. Alter, <u>Blood</u> , Vol. 85, No. 7, April 1, 1995; pp. 1681-1695.	
bf	BI	"Genotype-Dependent Serologic Reactivities in Patients Infected with Hepatitis C Virus in the United States", Nizar N. Zein, M.D. et al., <u>Mayo Clin. Proc.</u> , 1995; 70:449-452	
bf	BJ	"Improved serologic detection of hepatitis C virus with a paramagnetic microparticle assay using multiple antigenic sequences", D. Leahy et al., <u>Transfusion</u> , Vol. 32, No. 6, 1992, pp. 548-553	
bf	BK	"Genetic organization and diversity of the hepatitis C virus", Q.L. Choo et al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 88 March 1991, pp. 2451-2455	
bf	BL	Zhang et al., <u>Journal of Medical Virology</u> , 45:50-55, 1995.	
bf	BM	Bukh et al., <u>Proc. Natl. Acad. Sci. USA</u> , 91:8239-8243, August 1994.	
bf	BN	Chien et al., <u>Proc. Natl. Acad. Sci. USA</u> , 89:10011-10015, November 1992.	
bf	BO	Fields et al., <u>Clinical and Diagnostic Virology</u> 5:167-179, 1996.	
bf	BP	Ruedinger et al., Abstracts of the 97 <sup>th</sup> General Meeting of the American Society for Microbiology, Abstracts in Clinical and Diagnostic Immunology, # V-54, p. 583	
bf	BQ	Khudyakov, Yury et al., "New Frontiers in Protein Engineering: Artificial Mosaic Antigens", 17 <sup>th</sup> International Congress of Biochemistry and Molecular Biology in Conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology, San Francisco, California, USA, August 24-29, 1997, FASEB Journal 11 (9), 1997, abstract no. 1574.	
bf	BR	Chokri, Bahoul et al, "DNA-Based Immunization for Exploring the Enlargement of Immunological Cross-Reactivity Against the Lyssaviruses", Vaccine, Volume 16, No. 4, February 1998, pps. 417-425.	
EXAMINER		DATE CONSIDERED	
Freeda Trumbach		9-6-2001	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			